Nicola Fini

Nicola Fini

Auto-generated profile, based on publicly available information

Nicola Fini

Department of Neuroscience, S. Agostino- Estense Hospital, and University of Modena and Reggio Emilia, Modena, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
IDIlaria Di Donato
Ilaria Di Donato
AGAntonio Gallo
Antonio Gallo
IRIvana Ricca
Ivana Ricca
NFNicola Fini
Nicola Fini
Gabriella SilvestriGabriella Silvestri
Gabriella Silvestri
FSFilippo M. Santorelli
Filippo M. Santorelli
Mutations inPOLR3Aare characterized by high phenotypic heterogeneity, with manifestations ranging from severe childhood-onset hypomyelinating leukodystrophic syndromes to milder and later-onset gait disorders with central hypomyelination, with or without additional non-neurological signs. Recently, a milder phenotype consisting of late-onset spastic ataxia without hypomyelinating leukodystrophy has been suggested to be specific to the intronic c.1909 + 22G > A mutation inPOLR3A. Here, we present 10 patients from 8 unrelated families withPOLR3A-related late-onset spastic ataxia, all harboring the c.1909 + 22G > A variant. Most of them showed an ataxic-spastic picture, two a “pure” cerebellar phenotype, and one a “pure” spastic presentation. The non-neurological findings typically associated withPOLR3Amutations were absent in all the patients. The main findings on brain MRI were bilateral hyperintensity along the superior cerebellar peduncles on FLAIR sequences, observed in most of the patients, and cerebellar and/or spinal cord atrophy, found in half of the patients. Only one patient exhibited central hypomyelination. ThePOLR3Amutations present in this cohort were the c.1909 + 22G > A splice site variant found in compound heterozygosity with six additional variants (three missense, two nonsense, one splice) and, in one patient, with a novel large deletion involving exons 14–18. Interestingly, this patient had the most “complex” presentation among those observed in our cohort; it included some neurological and non-neurological features, such as seizures, neurosensory deafness, and lipomas, that have not previously been reported in association with late-onsetPOLR3A-related disorders, and therefore further expand the phenotype.

2 April 2020 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
Ilaria MartinelliIlaria Martinelli
Ilaria Martinelli
Elisabetta ZucchiElisabetta Zucchi
Elisabetta Zucchi
AGAnnalisa Gessani
Annalisa Gessani
NFNicola Fini
Nicola Fini
ACAdriano Chiò
Adriano Chiò
JESSICA MANDRIOLIJESSICA MANDRIOLI
JESSICA MANDRIOLI
Introduction: To date more than 180 different mutations in the SOD1 gene have been described in ALS; some of these mutations are associated to peculiar clinical features and have contributed to the understanding of disease heterogeneity. Only 5% of SOD1 mutations involve exon 3. Here we report a novel mutation c.197A > C in the exon 3 of the SOD1 gene in two apparently unrelated ALS families with early respiratory and cognitive impairment. Case report: In the first family two brothers developed ALS in their seventies, with arm weakness followed by bulbar involvement and behavioral breakdown. An unrelated 57-year-old man presented with progressive leg weakness and mild compromised executive functions without known family history for ALS/FTD and underwent invasive ventilation in a few months. A novel missense mutation A to C at codon 197 in exon 3 causing aminoacid substitution of arginine by threonine (N66T) was found for all of them. Harmful consequences of c.197A > C mutation on SOD1 function were suggested by in silico prediction and homology with other known mutations at the same position. Discussion and conclusion: Here, we report two apparently unrelated ALS families carrying a novel SOD1 mutation (N66T), supporting its pathogenic role by primary analysis, and characterized by early bulbar, respiratory, and cognitive involvement. Early cognitive impairment has been rarely described in ALS caused by SOD1 mutations, and mainly in the later phases of the disease. This report provides additional data on the SOD1 mutation spectrum and clinical presentation of ALS, widening phenotypical characterization of SOD1 ALS.

4 February 2023
Verified
Book Chapter
Closed access
UWUri Wormser
Uri Wormser
JESSICA MANDRIOLIJESSICA MANDRIOLI
JESSICA MANDRIOLI
Marco VincetiMarco Vinceti
Marco Vinceti
NFNicola Fini
Nicola Fini
ASAmnon Sintov
Amnon Sintov
YFYoram Finkelstein
Yoram Finkelstein
Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease) is a devastating incurable disease that involves motor neuron degeneration, stimulation of immune cells and increased inflammatory mediators in the nervous system. Alpha-1-antitrypsin (AAT) and IL-23 are immuno-modulatory/anti-inflammatory proteins involved in controlling inflammation-related pathologies. The present study determines AAT and IL-23 levels in the cerebrospinal fluid (CSF) of newly diagnosed ALS patients and age-matched controls. AAT levels in CSF of ALS patients were significantly reduced by 45% (21.4µg/ml) as compared to the control group (mean 38.8µg/ml, p=0.013). The pro-inflammatory cytokine IL-23 was significantly increased by 30.8% in CSF of ALS patients (1647pg/ml) in comparison to the controls (1259pg/ml, p=0.012). Linear regression analysis revealed a negative correlation coefficient (r=-0.543) of the two measured parameters (p=0.036). The notion of neuroinflammatory process occurring in ALS patients is further supported by the present findings showing reduction in the anti-inflammatory protein AAT and elevation in the pro-inflammatory cytokine IL-23 in CSF of ALS patients. Increasing AAT levels in the patients' nervous system, particularly via intranasal administration, should be considered as a potential therapeutic approach for ALS treatment.